12 results about "Liver disorder" patented technology

Methods of treating a subject for a liver condition, e.g., NAFLD, NASH, and / or DILI, are provided. Aspects of the methods include administering to the subject an effective amount of a UPase inhibitor, optionally in combination with a uridine active agent (e.g., uridine (UR), a UR pro-drug or a UR mimetic), such as supplemental uridine, to treat the subject for the liver condition. Also provided are compositions for use in practicing the subject methods.

The application discloses a prognosis risk prediction model construction system and method based on chronic disease real world data, comprising a multi-source real world data acquisition and access module, a data standardization and quality control module, a multi-dimensional feature engineering and screening module, a comorbidity feature fusion and data set construction module, a prognosis risk prediction model training and optimization module, a model multi-dimensional verification and evaluation module, a model deployment and risk stratification output module; a special multi-source real world data acquisition and quality control system for chronic liver disease, diabetes and hypertension is constructed, data standardization processing is realized in combination with a chronic disease clinical diagnosis and treatment guideline, through multi-dimensional missing value, abnormal value processing and data deduplication integration, the quality and availability of the real world data are effectively improved, the core problem of disorderly and low-quality real world data in the prior art is solved, and a high-quality data source basis is provided for model construction.

Disclosed herein are oral compositions of small molecule GLP-1 agonists and GIP / GLP-1 dual receptor agonists and uses thereof.

This document describes bile acid derivatives, their manufacturing methods, and their uses. These derivatives have shown potential as therapeutic agents for the treatment of liver diseases.

The application discloses a kind of chronic disease auxiliary drug curative effect evaluation and personalized recommendation method, comprising the following steps: step one: real world data acquisition, step two: data standardization and annotation, step three: curative effect evaluation model construction, step four: patient population stratification, step five: personalized drug recommendation, step six: data update and model iteration;The application is aimed at the clinical characteristics of three kinds of chronic diseases, liver disease, diabetes and hypertension, and constructs a multidimensional real world database and a targeted curative effect evaluation model, realizes the personalized and accurate recommendation of the auxiliary drug of the three kinds of chronic diseases, breaks through the limitation of single disease drug recommendation, effectively improves the clinical curative effect of auxiliary drug, reduces the risk of adverse drug reactions, and provides scientific support for the clinical rational use of drugs for the three kinds of chronic diseases.

Provided herein are isolated D-peptides having one or more D-amino acids, capable of affecting the neuroligin-4 (NLGN4)-neurexin 1β (Nrx1β) protein-protein interaction, wherein the D-peptide has improved human serum stability, enhanced ability to reduce activation of Hepatic Stellate Cells (HSCs) and / or attenuate their proliferation. Further provided are compositions including such peptides and uses thereof for treating and / or attenuating liver-related conditions.

Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).

The present disclosure relates to a drug combination and a method for the prevention and / or the treatment of a liver disease, the combination comprising lanifibranor or a deuterated form thereof and a GLP-1 / glucagon dual receptor agonist.

The application belongs to the technical field of biological medicine, and particularly relates to POFUT1 The application discloses an application of a gene function inhibitor in preparation of a drug for treating cholestatic liver disease. POFUT1 It is found for the first time that inhibition of the function of the gene can significantly reduce the degree of liver lesion of cholestatic liver disease. POFUT1 The deletion of the gene can significantly reduce serum liver enzyme, bile acid and bilirubin levels, reduce liver inflammatory cell infiltration and collagen deposition. Further verification by AAV8-mediated RNA interference technology shows that targeted silencing of the gene in liver cells can effectively alleviate liver injury and liver fibrosis. POFUT1 The application provides a novel treatment target and strategy for cholestatic liver disease, and has a wide clinical application prospect.

Disclosed herein are small molecule GIP / GLP-1 dual receptor agonist compositions, pharmaceutical compositions, the use and preparation thereof.

The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis, either alone or in combination with thyroid receptor agonists.

The application belongs to the technical field of biology, and discloses application of a gallic acid derivative VM in preparation of a product for treating or preventing liver diseases; the gallic acid derivative VM provided by the application has a significant inhibiting effect on accumulation of AST and ALT in alcohol-induced HepG2 cells, has a significant promoting effect on activity of ADH, and has good alcohol-induced liver injury protection activity; in acetylaminophenol (APAP)-induced HepG2 cells, the VM can significantly antagonize a significant decrease in GSH level of endogenous antioxidants in liver cells caused by APAP treatment, effectively maintains or even improves GSH reserves in the cells, indicates that the VM can enhance the antioxidant defense capacity of the cells, and can also significantly inhibit excessive generation of ROS induced by APAP, and has good acetylaminophenol-induced liver injury protection activity.